Ragon Institute of MGH, MIT and Harvard   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (2009)

Organization Overview

First Clinical Trial
2010
NCT01215149
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Ragon Institute | Ragon Institute of MGH, MIT and Harvard

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

HIV Infections (Phase 1)

Immunologic Deficiency Syndromes (Phase 1)

Inflammation (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 21